Vivus diet pill gets thumbs-down in Europe

European regulators aren't sold on the new Vivus weight loss pill. The Committee for Medicinal Products for Human use nixed Vivus' ($VVUS) application for approval, citing worries about Qsiva's safety and probable off-label use. The committee's rejection means Qsiva's European debut will be delayed for about 6 months--if not indefinitely. Sold as Qsymia in the U.S., the Vivus drug launched recently, accompanied by a barrage of media coverage. Story

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.